ArticleJournal of general internal medicine2026
Pharmacological Interventions for Alcohol Withdrawal Syndrome Among Hospitalized Adults: A Multicenter Cohort Study.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAlcohol Withdrawal Syndrome occurs in 1 in 43 hospitalized patients and is associated with increased morbidity. Pharmacotherapy for patients hospitalized with alcohol withdrawal syndrome are incompletely described. Understanding current practice patterns is essential to improving outcomes and addressing variability in care.
objectiveTo identify alcohol withdrawal syndrome treatment practice patterns across United States hospitals.
designMulticenter retrospective cohort study with data collected between quarter 1 of 2016 and quarter 3 of 2022 using Premier Incorporated Artificial Intelligence Healthcare Database (~ 25% of United States hospital admissions; excludes emergency room care).
participantsA total of 245,271 adult inpatients with a primary diagnosis of alcohol withdrawal syndrome. MAIN MEASURES: The outcomes were alcohol withdrawal syndrome medication treatment patterns, including initial treatment regimens, dosage trends, and factors associated with medication choice. KEY
resultsAmong 245,271 patients with alcohol withdrawal syndrome, 226,816 [92.5%] received benzodiazepines, 28,123 (11.5%) phenobarbital, and 113,746 (46.4%) other AWS agents within the first five days of admission. The most common initial treatment regimens were benzodiazepines alone (56.0%), benzodiazepines and other agents together (22.2%), and benzodiazepines and phenobarbital together (3.8%). Median daily benzodiazepine dose (diazepam equivalents) peaked on hospital day 2 (46.2 [interquartile range 23.1-84.2] mg), whereas median daily phenobarbital dose peaked on hospital day 1 (260 [120-520] mg). Type of medication used was associated with level of care at admission, hospital facility, and United States geographical region. In adjusted analyses, the admission hospital was associated with phenobarbital use (median odds ratio 4.21 [95% confidence interval 4.03-4.40]), benzodiazepine use (median odds ratio 3.09 [2.96-3.23]) and other agents (median odds ratio 1.65 [1.62-1.67]).
conclusionsAlcohol withdrawal syndrome treatment varied by level of care at admission and hospital, highlighting significant variability in practice patterns. These findings inform future trials comparing the effectiveness of different medication regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.